Payment overview · 2025
General Payments
$93,484.86
180 reported records · 15 companies
Healthcare provider profile · identity verified
David M Kayne, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ENCINO, CA · NPI 1144334533
Verified facts
What the public records show
CMS Open Payments records show David M Kayne, M.D. received $93,484.86 in general payments during 2025 across 180 reported records.
Lilly USA, LLC accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Mounjaro, Ozempic, Rybelsus, Trulicity.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32,251.97 | 34.5% | 46 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21,596.84 | 23.1% | 27 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19,366.93 | 20.7% | 40 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $8,670.23 | 9.3% | 15 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8,123.61 | 8.7% | 16 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $1,687.50 | 1.8% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $672.53 | 0.7% | 15 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $363.87 | 0.4% | 6 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $271.23 | 0.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $241.70 | 0.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $122.07 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.68 | 0.0% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $32.03 | 0.0% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $27.71 | 0.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.96 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,193.94 | 40 |
| Travel and Lodging | $9,489.95 | 53 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,788.00 | 2 |
| Consulting Fee | $7,424.50 | 4 |
| Honoraria | $7,200.00 | 4 |
| Food and Beverage | $4,356.20 | 76 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25,440.18 | 37 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $19,366.93 | 40 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19,028.82 | 22 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $8,498.56 | 8 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $8,498.56 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $8,123.61 | 16 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $672.53 | 15 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $363.87 | 6 | 2025 |
Source payment records
|
|||||
| TRULICITY Normalized: trulicity |
Drug | Lilly USA, LLC | $325.00 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $271.23 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $271.23 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $271.23 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $241.70 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $171.67 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $139.13 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32.03 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $20.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 241 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRULICITY trulicity |
2025 | Trulicity | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
241 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
241 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 102 |
| Mounjaro | Tirzepatide | 241 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 56 |
| Metformin Hcl | Metformin Hcl | 174 | 48 |
| Ozempic | Semaglutide | 162 | 27 |
| Irbesartan | Irbesartan | 156 | 43 |
| Synthroid | Levothyroxine Sodium | 155 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 47 |
| Losartan Potassium | Losartan Potassium | 148 | 35 |
| Ezetimibe | Ezetimibe | 133 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 30 |
| Jardiance | Empagliflozin | 90 | 21 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Allopurinol | Allopurinol | 89 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 30 |
| Alprazolam | Alprazolam | 87 | 30 |
| Farxiga | Dapagliflozin Propanediol | 83 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 25 |
| Omeprazole | Omeprazole | 80 | 23 |
| Azithromycin | Azithromycin | 78 | 62 |
| Potassium Chloride | Potassium Chloride | 74 | 27 |
| Glimepiride | Glimepiride | 71 | 17 |
| Simvastatin | Simvastatin | 71 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 26 |
| Tramadol Hcl | Tramadol Hcl | 67 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 67 | 16 |
| Trazodone Hcl | Trazodone Hcl | 66 | 17 |
| Januvia | Sitagliptin Phosphate | 63 | 11 |
| Tradjenta | Linagliptin | 63 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 62 | 61 |
| Gabapentin | Gabapentin | 59 | 21 |
| Methylprednisolone | Methylprednisolone | 57 | 47 |
| Repatha Sureclick | Evolocumab | 57 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 15 |
| Meloxicam | Meloxicam | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 12 |
| Furosemide | Furosemide | 51 | 18 |
| Humalog | Insulin Lispro | 49 | 14 |
| Lisinopril | Lisinopril | 47 | 11 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 17 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Invokana | Canagliflozin | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Famotidine | Famotidine | 38 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 11 |
| Prednisone | Prednisone | 37 | 15 |
| Eliquis | Apixaban | 36 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Livalo | Pitavastatin Calcium | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Afrezza | Insulin Regular, Human | 27 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 26 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Kerendia | Finerenone | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | 14 |
| Testosterone | Testosterone | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 13 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93,484.86 · 180 records | Lilly USA, LLC | AFREZZA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, GVOKE HYPOPEN, Korlym, LifeVest, MINIMED 780G, MOUNJARO, OMNIPOD, Ozempic, Rybelsus, Saxenda, TRULICITY, TWIIST, The Cologuard Plus Collection Kit, Wegovy, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Eli Lilly and Company?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error